- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
APG3L Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP1807a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
APG3L Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | Q9NT62 |
| Clone Names | 5012701 |
| Calculated MW | 35864 Da |
APG3L Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 64422 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP1807a was selected from the N-term region of human Autophagy APG3L. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
APG3L Antibody (N-term) Blocking Peptide - Protein Information | |
| Name ATG3 | |
| Synonyms APG3, APG3L | |
| Function E2-like enzyme involved in autophagy and mitochondrial homeostasis. Catalyzes the conjugation of ATG8-like proteins (GABARAP, GABARAPL1, GABARAPL2 or MAP1LC3A) to phosphatidylethanolamine (PE). PE-conjugation to ATG8-like proteins is essential for autophagy. Preferred substrate is MAP1LC3A. Also acts as an autocatalytic E2-like enzyme, catalyzing the conjugation of ATG12 to itself, ATG12 conjugation to ATG3 playing a role in mitochondrial homeostasis but not in autophagy ATG7 (E1-like enzyme) facilitates this reaction by forming an E1- E2 complex with ATG3 | |
| Cellular Location Cytoplasm. | |
| Tissue Location Widely expressed, with a highest expression in heart, skeletal muscle, kidney, liver and placenta | |
APG3L Antibody (N-term) Blocking Peptide - Related products
AP1807a: ATG3 Antibody (N-term)
AP1807b: ATG3 Antibody (C-term)
AP1807c: ATG3 Antibody (C-term K183)
AP3430a: Phospho-ATG3-Y18 Antibody
AP3740a: Phospho-APG3 - cleaved Antibody
LY11891a: ATG3 Over-expression Lysate
BP1807a: APG3L Antibody (N-term) Blocking Peptide
BP1807b: APG3L Antibody (C-term) Blocking Peptide
BP1807c: APG3L Antibody (C-term K183) Blocking Peptide
BP1807e: APG3L Antibody (Y18) Blocking Peptide
BP1833a: cleaved-APG3 Antibody Blocking Peptide
APG3L Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG3L is an E2-like conjugating enzyme facilitating covalent binding of APG8 (MAP1LC3) to phosphatidylethanolamine (PE). APG7 (an E1-like enzyme) facilitates this reaction by forming an E1-E2 complex with APG3. Formation of the PE conjugate is essential for autophagy.
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)
